Clinical Trials Browser

Rectal Neoplasms × Irinotecan × 90 days × Clear all

Colonic Neoplasms, Rectal Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04215731 2026-03-03

FOBEAR

Phase 3 Recruiting

582 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

240 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

42 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02314182 2025-12-19

GRECCAR8

Phase 3 Completed

5 enrolled

Gastrointestinal

Rectal Neoplasms

Clinical Trials

SCOTI

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

FOBEAR

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

GRECCAR8